Surmodics

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Surmodics reports Q1 growth, FDA hurdles, and strategic partnerships

Surmodics navigates FDA challenges with the SurVeil application while focusing on cost-saving measures and revenue growth strategies for fiscal 2023.
The company's strong technology foundation, partnership with Abbott, and customer acceptance of key products position it well for future growth.
Despite challenges in FDA approval and spending reductions, Surmodics remains committed to innovation, regulatory compliance, and strategic partnerships.
Opportunities in product commercialization, revenue growth, and asset preservation offer avenues for overcoming challenges and driving long-term success.

Surmodics reports solid Q2 growth, navigates FDA approvals and revenue challenges

Surmodics shows strong performance in medical device sales and strategic objectives execution.
Challenges include In Vitro Diagnostics revenue decline and revised fiscal guidance.
Opportunities lie in significant sales growth projections and regulatory milestones.
Financial stability maintained through cash utilization plan and spending reduction measures.
Overall, Surmodics navigates growth and challenges with a focus on FDA approvals and revenue growth.

Surmodics excels in Q3 with robust revenue growth and strategic partnerships

Surmodics delivered exceptional Q3 results, driven by strong revenue growth and operational achievements, setting the stage for continued success.
The company's focus on cash flow generation, disciplined expense management, and strategic partnerships with Abbott bode well for future growth and profitability.
While facing challenges such as COVID-related impacts and revenue sharing negotiations, Surmodics remains poised to capitalize on opportunities for growth and innovation.
With a solid financial position, expanded revenue guidance, and readiness to support Abbott's commercial initiatives, Surmodics is well-positioned for a promising future.

Surmodics reports robust Q4 earnings, eyes growth amidst challenges

Surmodics delivered strong financial performance in Q4 2023 and fiscal 2023, driven by revenue growth and operational improvements.
While facing challenges such as competitive dynamics and projected losses in fiscal 2024, the company is well-positioned to capitalize on opportunities.
Strategic achievements, product advancements, and financial stability position Surmodics for continued growth and market success in the coming year.
Emphasis on innovation, market expansion, and cost management will be crucial for Surmodics to navigate challenges and leverage growth opportunities.

Surmodics reports robust Q1 growth, eyes new product launches

Surmodics' Q1 2024 performance reflects strong revenue growth, operational efficiency, and successful product launches, positioning the company for continued success in the medical device and diagnostics markets.
While challenges such as incremental expenses and pricing dynamics exist, Surmodics' focus on innovation, financial discipline, and market responsiveness presents opportunities for sustained growth and competitive advantage.
With a strategic outlook towards driving revenue growth, expanding product offerings, and optimizing expenses, Surmodics aims to navigate challenges and capitalize on opportunities for long-term success and market leadership.

Surmodics reports robust Q2 growth, eyes profitability amid challenges

Surmodics' Q2 2024 performance reflects revenue growth, improved profitability, and product innovation, underpinned by strong R&D focus and strategic partnerships.
While facing challenges in achieving profitability and providing clear guidance for fiscal 2025, the company remains optimistic about growth opportunities and market expansion.
With a focus on enhancing margins, expanding product offerings, and leveraging partnerships, Surmodics is poised for continued growth and innovation in the medical device industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures vascular interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

NEW YORK--( BUSINESS WIRE )--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX). Investors who purchased Surmodics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/srdx.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Surmodics, Inc. (SRDX) Investigation

NEW YORK--( BUSINESS WIRE )--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Li Auto may have issued materially misleading business information to the investing public.

SRDX EQUITY ALERT: Rosen Law Firm Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX

EDEN PRAIRIE, Minn.--( BUSINESS WIRE )--Surmodics, Inc. (NASDAQ:SRDX) (the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the differentiated capabilities of its crystalline drug release (CDR) platform for sirolimus-coated balloons (SCBs) were discussed in connection with 12-month data from the Company's SWING trial at the 35th annual International Symposium on Endovascular Therapy (ISET) in Miami, Florida. The SWING trial is a first-in-human feasibility study of the Company's Sundance™ SCB.

Differentiated Capabilities of Surmodics' Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference

EDEN PRAIRIE, Minn.--( BUSINESS WIRE )--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has received a letter from the U.S. Food and Drug Administration (FDA; the Agency) related to its premarket approval (PMA) application for the SurVeil™ drug-coated balloon (DCB).

Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated Balloon

EDEN PRAIRIE, Minn.--( BUSINESS WIRE )--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Professor Ramon Varcoe will present 12-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon (DCB). The session will be held on Wednesday, January 18, at the 35th annual International Symposium on Endovascular Therapy (ISET) conference in Miami, Florida. Professor Varcoe will also discuss the differentiated capabilities of the Surmodics crystalline drug release platform for sirolimus-coated balloons (SCBs) in connection with 12-month data from the SWING trial.

Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

3 Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio

EDEN PRAIRIE, Minn.--( BUSINESS WIRE )--Surmodics, Inc. (NASDAQ:SRDX) (the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 12-month data from the SWING Trial, a first-in-human study of the Company's Sundance™ Sirolimus drug-coated balloon (DCB) was presented at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium) in New York City.

Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium

Surmodics, Inc. (NASDAQ:SRDX ) Q4 2022 Earnings Conference Call November 9, 2022 10:00 AM ET Company Participants Gary Maharaj - CEO, President & Director Timothy Arens - SVP, Finance & Information Technology & CFO Conference Call Participants Michael Petusky - Barrington Research Associates Brooks O'Neil - Lake Street Capital Markets James Sidoti - Sidoti & Company Michael Matson - Needham & Company Operator Welcome everyone to Surmodics' Fourth Quarter and Fiscal Year 2022 Earnings Call. Please note that this call is being webcast.

Surmodics, Inc. (SRDX) Q4 2022 Earnings Call Transcript

EDEN PRAIRIE, Minn.--( BUSINESS WIRE )--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Professor Ramon Varcoe will present 12-month data from the SWING Trial, a first-in-human study of the safety and efficacy of the Sundance™ Sirolimus Drug-Coated Balloon (DCB). The session will be held on Wednesday, November 16, at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium) in New York City.

Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16

Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust Medical Device revenues.

Surmodics (SRDX) Q4 Earnings and Revenues Top Estimates

Surmodics Reports Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Financial Guidance

Abbott Labs

24-Month Data from Surmodics' TRANSCEND Trial Presented at VIVA 2022 Conference

Surmodics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on November 9th

Surmodics Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022

Surmodics Announces New Credit Facilities Providing up to $125 Million in Financing

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Acquisition--6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe

6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Acquisition--6-Month Data from the Surmodics SWING First-in-Human Study to be Presented at AMP Europe

6-Month Data from the Surmodics SWING First-in-Human Study to be Presented at AMP Europe

Here's Why You Should Hold on to Surmodics (SRDX) Stock Now

3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Acquisition--Surmodics to Present at Upcoming Gilmartin Emerging Growth Company Showcase Wednesday, August 31, 2022.

Surmodics to Present at Upcoming Gilmartin Emerging Growth Company Showcase Wednesday, August 31, 2022

Product sales primarily drive Surmodics' (SRDX) third-quarter top-line growth. However, the company expects softer demand for its products and services in the second half of 2022.

Surmodics (SRDX) Beats on Q3 Earnings, Revises FY22 View

Surmodics, Inc. (NASDAQ:SRDX ) Q3 2022 Earnings Conference Call July 27, 2022 8:30 AM ET Company Participants Gary Maharaj - President and Chief Executive Officer Tim Arens - Senior Vice President of Finance and Information Technology and Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Jim Sidoti - Sidoti & Company Mike Matson - Needham & Company Operator Good day, and welcome to the Surmodics' Third Quarter Fiscal 2022 Earnings Conference Call. Today's conference is being recorded.

Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q3 2022 Results - Earnings Call Transcript

SurModics (SRDX) delivered earnings and revenue surprises of 12.82% and 2.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics Reports Third Quarter Fiscal 2022 Results

Surmodics Reports Third Quarter Fiscal 2022 Results

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Catheter--Surmodics to Webcast Third Quarter Fiscal 2022 Earnings Conference Call on July 27. Webcast is Live at 7:30 a.m. (CT)

News for Surmodics Stock (SRDX)